PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced preliminary worldwide net revenue for the first quarter of 2015.
The Company expects worldwide net revenue in the range of $125 million to $130 million for the first quarter of 2015, which reflects a 29% to 26% decrease from the $177.2 million in worldwide net revenue reported for the first quarter of 2014. The decrease in worldwide net revenue is a result of lower worldwide net revenue from sales of Angiomax® (bivalirudin)/Angiox® (bivalirudin), which the Company expects to be in the range of $97 million to $105 million compared to $155.7 million in the first quarter of 2014.
Help employers find you! Check out all the jobs and post your resume.
The Company expects worldwide net revenue in the range of $125 million to $130 million for the first quarter of 2015, which reflects a 29% to 26% decrease from the $177.2 million in worldwide net revenue reported for the first quarter of 2014. The decrease in worldwide net revenue is a result of lower worldwide net revenue from sales of Angiomax® (bivalirudin)/Angiox® (bivalirudin), which the Company expects to be in the range of $97 million to $105 million compared to $155.7 million in the first quarter of 2014.
Help employers find you! Check out all the jobs and post your resume.
